La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
